PubMed Health⌕ Search

PubMed · 2099113

[Urinary iodide determination by X-ray fluorescence].

Abstract

Urinary iodide measurement has been carried out by X-ray-fluorescence, either directly on urinary solution, or after matrix concentration. Proportionality between emitted XK alpha rays of iodine and iodide mass in standards has been observed on a large scale, ranging up to 400 micrograms. With an exciting-1.11 GBq (241(95) Am)-radioactive source, 0.44 microgram are detected for solid matrix, and 0.9 microgram/ml for iodide in solution for 10 mn measuring time. So direct measurement on solution can be applied only to high excreted iodide. For normal range iodide determination is performed after anionic resin concentration (on 100 ml or 200 ml). For tracing, Na I131 is employed. The binding ratio is strongly depending on flow, resin weight, and associate urinary anionic components. On 20 healthy subjects, normal range value is 53 +/- 22 micrograms/l (m +/- s.d.). Comparative study with an electrochemical method showed fluorescence iodide values are lower than the former. The proposed method is very simple, one or two steps (function of iodide content). As no interfered Rx has been observed in the Rx iodide region, the authors can ascertain that accurate values are observed by X-ray fluorescence. In case of high iodide content, this methods allows to distinguish urinary iodide versus total urinary iodine, when performing solution and matrix concentration studies on the urinary batch.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Turzo, J M Legendre, R Quiniou, P P Morin. 1990. [Urinary iodide determination by X-ray fluorescence].. https://pubmed.ncbi.nlm.nih.gov/2099113/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗